Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sparfloxacin is a synthetic fluoroquinolone antibiotic used to treat bacterial respiratory infections such as bronchitis and pneumonia, as well as sinusitis. It acts by inhibiting bacterial DNA gyrase, an essential enzyme for DNA replication, repair, deactivation, and transcription in bacteria. This inhibition disrupts bacterial cell division and leads to cell death. Sparfloxacin exhibits broad-spectrum activity against both gram-positive and gram-negative organisms. It has been withdrawn from the U.S. market due to safety concerns but may still be available elsewhere[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sparfloxacin.